Reference : Pharma-clinics le medicament du mois. Le naratriptan (naramig).

	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Pharmacy, pharmacology & toxicology
	To cite this reference:	http://hdl.handle.net/2268/12577

Title :	Pharma-clinics le medicament du mois. Le naratriptan (naramig).
Language :	French
Alternative title :	[fr] Pharmacy-clinic medication of the month. Naratriptan (naramig)
Author, co-author :	Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Publication date :	1999
Journal title :	Revue Médicale de Liège
Publisher :	Hopital de Baviere
Volume :	54
Issue/season :	3
Pages :	189-91
ISSN :	0370-629X
City :	Liège
Country :	Belgique
Keywords :	[en] Drug Administration Schedule ; Humans ; Indoles/administration & dosage/pharmacology/therapeutic use ; Migraine Disorders/drug therapy ; Piperidines/administration & dosage/pharmacology/therapeutic use ; Serotonin Agonists/administration & dosage/pharmacology/therapeutic use ; Tryptamines
Abstract :	[en] Naratriptan, launched by Glaxo Wellcome under the trade name Naramig, is a potent and selective agonist of 5-HT1B and 5-HT1D vascular receptors. Available as tablets of 2.5 mg, it is indicated in the acute treatment of migraine, with or without aura. A single oral dose of 2.5 mg naratriptan is characterized by a satisfactory clinical efficacy (already significant after one hour, maximum after 4 hours and persisting during 24 hours), a reduction by half of the recurrence of the migraine crisis within the 24 hours and an excellent tolerance profile.
Permalink :	http://hdl.handle.net/2268/12577

There is no file associated with this reference.

All documents in ORBi are protected by a user license.

 

© ULg Library Network |  Feedback |  ORBi legal notices

Dspace v1.5